← Back to Clinical Trials
Recruiting Phase 3 NCT04415983

NCT04415983 Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04415983
Status Recruiting
Phase Phase 3
Sponsor Tanta University
Condition Helicobacter Pylori Infection
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2020-06-01
Primary Completion 2030-10-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
NitazoxanideClarithromycinMetronidazole

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.

This trial targets 100 participants in total. It began in 2020-06-01 with a primary completion date of 2030-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Study of Nitazoxanide (NTZ) based therapeutic regimens for Helicobacter pylori in children

Eligibility Criteria

Inclusion Criteria: \- Positive helicobacter infection. Exclusion Criteria: * Previous treatment for H. Pylori.

Contact & Investigator

Central Contact

Sherief Abd-Elsalam, ass. prof.

✉ sheriefabdelsalam@yahoo.com

📞 00201147773440

Principal Investigator

Rasha Gamal, Ass. Prof.

PRINCIPAL INVESTIGATOR

Pediatrics department - Tanta University

Frequently Asked Questions

Who can join the NCT04415983 clinical trial?

This trial is open to participants of all sexes, up to 18 Years, studying Helicobacter Pylori Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT04415983 trial and what does that mean for participants?

Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 100 participants.

Is NCT04415983 currently recruiting?

Yes, NCT04415983 is actively recruiting participants. Contact the research team at sheriefabdelsalam@yahoo.com for enrollment information.

Where is the NCT04415983 trial being conducted?

This trial is being conducted at Tanta, Egypt.

Who is sponsoring the NCT04415983 clinical trial?

NCT04415983 is sponsored by Tanta University. The principal investigator is Rasha Gamal, Ass. Prof. at Pediatrics department - Tanta University. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology